Brokers Offer Predictions for LeMaitre Vascular, Inc.’s Q4 2022 Earnings (NASDAQ:LMAT)

LeMaitre Vascular, Inc. (NASDAQ:LMATGet Rating) – Equities research analysts at Jefferies Financial Group lowered their Q4 2022 EPS estimates for LeMaitre Vascular in a report issued on Thursday, July 28th. Jefferies Financial Group analyst Z. Weiner now forecasts that the medical instruments supplier will post earnings of $0.31 per share for the quarter, down from their previous forecast of $0.32. The consensus estimate for LeMaitre Vascular’s current full-year earnings is $1.25 per share.

Separately, Barrington Research decreased their price objective on shares of LeMaitre Vascular from $54.00 to $50.00 in a research report on Friday, April 29th.

LeMaitre Vascular Trading Up 3.1 %

LMAT stock opened at $50.35 on Monday. The firm’s 50-day moving average price is $45.61 and its two-hundred day moving average price is $44.85. LeMaitre Vascular has a 12-month low of $38.32 and a 12-month high of $60.79. The stock has a market capitalization of $1.11 billion, a price-to-earnings ratio of 40.28 and a beta of 1.22.

LeMaitre Vascular (NASDAQ:LMATGet Rating) last released its quarterly earnings data on Thursday, April 28th. The medical instruments supplier reported $0.27 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). LeMaitre Vascular had a net margin of 17.09% and a return on equity of 11.41%. The firm had revenue of $39.56 million during the quarter, compared to analysts’ expectations of $38.65 million. During the same quarter in the previous year, the firm posted $0.28 EPS. LeMaitre Vascular’s revenue was up 10.2% compared to the same quarter last year.

Institutional Investors Weigh In On LeMaitre Vascular

Hedge funds and other institutional investors have recently bought and sold shares of the business. Everence Capital Management Inc. bought a new position in shares of LeMaitre Vascular in the first quarter worth approximately $257,000. Raymond James & Associates lifted its position in LeMaitre Vascular by 37.4% during the fourth quarter. Raymond James & Associates now owns 14,456 shares of the medical instruments supplier’s stock valued at $726,000 after purchasing an additional 3,934 shares during the period. Personal CFO Solutions LLC lifted its position in LeMaitre Vascular by 4.4% during the first quarter. Personal CFO Solutions LLC now owns 6,485 shares of the medical instruments supplier’s stock valued at $301,000 after purchasing an additional 275 shares during the period. Yousif Capital Management LLC bought a new position in LeMaitre Vascular during the fourth quarter valued at approximately $856,000. Finally, Grandeur Peak Global Advisors LLC lifted its position in LeMaitre Vascular by 0.9% during the fourth quarter. Grandeur Peak Global Advisors LLC now owns 314,076 shares of the medical instruments supplier’s stock valued at $15,776,000 after purchasing an additional 2,931 shares during the period. Hedge funds and other institutional investors own 84.90% of the company’s stock.

LeMaitre Vascular Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 8th. Shareholders of record on Thursday, August 25th will be issued a $0.125 dividend. This represents a $0.50 dividend on an annualized basis and a yield of 0.99%. The ex-dividend date is Wednesday, August 24th. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 40.00%.

LeMaitre Vascular Company Profile

(Get Rating)

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system.

See Also

Earnings History and Estimates for LeMaitre Vascular (NASDAQ:LMAT)

Want More Great Investing Ideas?

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.